De Castro, Nathalie
Brun, Alexandre
Sellier, Pierre
Hamet, Gwenn
Mechaï, Frédéric
Garrait, Valérie
Chabrol, Amélie
Bouldouyre, Marie-Anne
Froguel, Eric
Troisvallets, Didier
Caraux-Paz, Pauline
Delaugerre, Constance
Rozenbaum, Willy
Molina, Jean-Michel
Funding for this research was provided by:
Gilead Sciences (The Voice program 2015)
Article History
Received: 7 March 2022
Accepted: 19 December 2022
First Online: 3 January 2023
Declarations
:
: NDC received a research Grant from Gilead in 2015 for the present work. JMM has acted as a consultant, participated in advisory boards, has received speaker fees and has been an investigator for clinical trials for Janssen, ViiV Healthcare, Gilead Sciences, Bristol-Myers Squibb, Abbott Laboratories, Boehringer Ingelheim, and Merck, Sharp & Dohme. He has also received research grants from Merck. CD participated in advisory boards for ViiV Healthcare, Gilead Sciences, BMS, and Merck, and has also received research grants from Gilead, and MAD. DT received fees for travel and conferences by Gilead and MSD.